These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10233638)

  • 21. Hydroxyurea in the management of therapy resistant psoriasis.
    Layton AM; Sheehan-Dare RA; Goodfield MJ; Cotterill JA
    Br J Dermatol; 1989 Nov; 121(5):647-53. PubMed ID: 2597635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nail pigmentation due to hydroxycarbamide.
    Ceulen RP; Frank J; Poblete-Gutiérrez P
    Int J Dermatol; 2007 Nov; 46 Suppl 3():13-5. PubMed ID: 17973880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hydroxyurea in the treatment of psoriasis].
    Borisenko KK; Rodionova GV
    Vestn Dermatol Venerol; 1974 Oct; 0(10):63-6. PubMed ID: 4432618
    [No Abstract]   [Full Text] [Related]  

  • 26. Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection.
    Grunke M; Dechant C; Löw P; Rascu A; Kalden JR; Harrer T
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):424-6. PubMed ID: 10458626
    [No Abstract]   [Full Text] [Related]  

  • 27. Fever caused by hydroxyurea.
    Bauman JL; Shulruff S; Hasegawa GR; Roden R; Hartsough N; Bauernfeind RA
    Arch Intern Med; 1981 Feb; 141(2):260-1. PubMed ID: 7458524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety].
    de Montalembert M
    Transfus Clin Biol; 2008; 15(1-2):34-8. PubMed ID: 18499496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
    Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermatomyositis-like eruption with long-term hydroxyurea.
    Elliott R; Davies M; Harmse D
    J Dermatolog Treat; 2006; 17(1):59-60. PubMed ID: 16467027
    [No Abstract]   [Full Text] [Related]  

  • 31. Thioguanine for refractory psoriasis: a 4-year experience.
    Mason C; Krueger GG
    J Am Acad Dermatol; 2001 Jan; 44(1):67-72. PubMed ID: 11148479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern treatment of thalassaemia intermedia.
    Borgna-Pignatti C
    Br J Haematol; 2007 Aug; 138(3):291-304. PubMed ID: 17565568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up.
    Mancuso A; Maggio A; Renda D; Di Marzo R; Rigano P
    Br J Haematol; 2006 Apr; 133(1):105-6. PubMed ID: 16512837
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxyurea in the treatment of HIV-1.
    Gibbs MA; Sorensen SJ
    Ann Pharmacother; 2000 Jan; 34(1):89-93. PubMed ID: 10669190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
    AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of immune modulation in primary HIV infection.
    Lori F; Lisziewicz J
    J Biol Regul Homeost Agents; 2000; 14(1):45-8. PubMed ID: 10763893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unusual dermatological toxicity of hydroxyurea in two dogs with spontaneously occurring tumours.
    Marconato L; Bonfanti U; Fileccia I
    J Small Anim Pract; 2007 Sep; 48(9):514-7. PubMed ID: 17617162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F; Bejaoui M
    Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spurious glycohemoglobin values associated with hydroxyurea treatment.
    Karsegard J; Wicky J; Mensi N; Caulfield A; Philippe J
    Diabetes Care; 1997 Jul; 20(7):1211-2. PubMed ID: 9203471
    [No Abstract]   [Full Text] [Related]  

  • 40. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.